157 related articles for article (PubMed ID: 37625683)
1. PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer.
Zhao S; Li Y; Li G; Ye J; Wang R; Zhang X; Li F; Gao C; Li J; Jiang J; Mi Y
Eur J Pharmacol; 2023 Oct; 957():176004. PubMed ID: 37625683
[TBL] [Abstract][Full Text] [Related]
2. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
3. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
4. Luteoloside induces G
Zhou M; Shen S; Zhao X; Gong X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.
Gao J; Huang W; Zhao S; Wang R; Wang Z; Ye J; Lin L; Cai W; Mi Y
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23590. PubMed ID: 38037286
[TBL] [Abstract][Full Text] [Related]
6. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Nie P; Hu W; Zhang T; Yang Y; Hou B; Zou Z
Cell Physiol Biochem; 2015; 35(6):2255-71. PubMed ID: 25895606
[TBL] [Abstract][Full Text] [Related]
8. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
10. Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer.
Teng JF; Qin DL; Mei QB; Qiu WQ; Pan R; Xiong R; Zhao Y; Law BY; Wong VK; Tang Y; Yu CL; Zhang F; Wu JM; Wu AG
Pharmacol Res; 2019 Sep; 147():104396. PubMed ID: 31404628
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
13. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
15. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
16. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
18. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
19. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
20. GDC-0349 inhibits non-small cell lung cancer cell growth.
Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G
Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]